--- title: Qubit Pharmaceuticals Selected as a 2024 WEF Technology Pioneer image: https://blog.qubit-pharmaceuticals.com/hubfs/cite-innovation-rub_0.jpg --- [Skip to content](https://blog.qubit-pharmaceuticals.com/qubit-pharmaceuticals-selected-as-one-of-the-100-technology-pioneers-2024-by-the-world-economic-forum#main-content) [![Qubit-black](https://blog.qubit-pharmaceuticals.com/hs-fs/hubfs/Qubit-black.png?width=634&height=200&name=Qubit-black.png)](https://www.qubit-pharmaceuticals.com/) Open main navigation Close main navigation - [Contact us](mailto:contact@qubit-pharmaceuticals.com) [Contact us](mailto:contact@qubit-pharmaceuticals.com) ## Press Release June 6, 2024 # Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum - **Qubit Pharmaceuticals joins the prestigious community of 100 disruptive technology startups.** - **Over the next 2 years, the company will participate in numerous events and have opportunities to meet with key decision-makers in business, politics and academia.** - **Qubit Pharmaceuticals is invited to the “Summer Davos” event in Dalian, China, from June 25 to 27.** **Paris, June 6, 2024** - Qubit Pharmaceuticals, a deeptech company specialised discovering novel drug candidates through simulation and molecular modeling powered by hybrid HPC and quantum computing, announces that its selection as a 2024 *Technology Pioneer* by the World Economic Forum in Davos. Launched in 2000, the WEF’s *Technology Pioneer* community now boasts over 1,000 award winners, including many of the world's most innovative companies. Each year, the Forum honors a group of 100 leading technology startups, deploying technologies that are likely to have a major impact in the future. By associating themselves with the Forum's initiatives, the *Technology Pioneers* contribute, alongside industry leaders and political decision-makers, to tackling the world's major challenges. As a Technology Pioneer, Qubit Pharmaceuticals will, over the next two years, gain access to numerous high-level events and opportunities to engage with decision-makers from business, politics, academia, and civil society. Qubit Pharmaceuticals has already been invited to the next annual meeting of the Forum's New Laureates, or “Summer Davos”, to be held in Dalian, China, from June 25 to 27. > **Robert Marino, CEO of Qubit Pharmaceuticals**, says: “*We are delighted to join the prestigious community of Technology pioneers at the Davos Forum. This selection honors us and further highlights our outstanding technology. There is no doubt that the World Economic Forum's unrivalled network will also enable us to accelerate the implementation of our ambitions.”* **Accelerating drug discovery with hybrid HPC and quantum computing** With a team of 60 experts in quantum chemistry, computational chemistry, machine-learning and medicinal chemistry, Qubit Pharmaceuticals has leveraged spercomputers and quantum computers to develop is Atlas drug discovery platform. This platform aims to reduce the time requires to screen, select and optimize a candidate of interest by half, while decreasing the necessary investment more than tenfold. --- **About Qubit Pharmaceuticals** Qubit Pharmaceuticals was founded in 2020 with the vision of co-developing new, more effective and safer drugs with pharmaceutical and biotech companies. A spin-off from the research work of five internationally renowned scientists - Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne University and CNRS), Jay Ponder (Washington University in St Louis), Pengyu Ren (University of Texas at Austin) - Qubit Pharmaceuticals leverages its Atlas platform to discover new drugs through simulation and molecular modeling accelerated by hybrid HPC and quantum computing. The multidisciplinary team, led by CEO Robert Marino, and the founders are based in France at the Paris Santé Cochin incubator and in the USA in Boston. For more information, or to join an ambitious team, visit [www.qubit-pharmaceuticals.com](http://www.qubit-pharmaceuticals.com/) **About the « Technology Pioneers » community of the Davos Forum (WEF)** DistriQ, Sherbrooke's Quantum Innovation Zone, is a non-profit organization (NPO) that brings quantum technologies to life by supporting all stages of innovation, from university research to the commercialization of quantum technologies. DistriQ supports the development of Sherbrooke's collaborative ecosystem by bringing together quantum players, offering research infrastructure, and building bridges with major companies that are potential users of quantum technologies. --- **Press contacts** Nicolas Daniels – [ndaniels@ulysse-communication.com](mailto:ndaniels@ulysse-communication.com) – +33 (0)6.66.59.22.63 Charles Courbet – [ccourbet@ulysse-communication.com](mailto:ccourbet@ulysse-communication.com) - + 33 (0)6.28.93.03.06 ![Fichier 1@4x](https://blog.qubit-pharmaceuticals.com/hs-fs/hubfs/AI%20molecular/Fichier%201@4x.png?width=2000&height=671&name=Fichier%201@4x.png "Fichier 1@4x") [linkedin-in icon](https://www.linkedin.com/company/qubit-pharmaceuticals/) [X Twitter icon](https://x.com/qubit_pharma) --- [![Logo Qubit Pharmaceuticals](https://blog.qubit-pharmaceuticals.com/hs-fs/hubfs/qubit-logo@2x%20(1)-1.png?width=750&height=225&name=qubit-logo@2x%20(1)-1.png "Logo Qubit Pharmaceuticals")](https://blog.qubit-pharmaceuticals.com/?hsLang=en) 29, rue du Faubourg, 75014 Paris, France Copyright © 2024, All Rights Reserved.